These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15199445)

  • 21. Tirofiban in acute coronary syndromes.
    Menozzi A; Merlini PA; Ardissino D
    Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):193-206. PubMed ID: 15853593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of platelets in restenosis after percutaneous coronary revascularization.
    Le Breton H; Plow EF; Topol EJ
    J Am Coll Cardiol; 1996 Dec; 28(7):1643-51. PubMed ID: 8962547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
    Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
    Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrin alphaIIbbeta3 and its antagonism.
    Quinn MJ; Byzova TV; Qin J; Topol EJ; Plow EF
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):945-52. PubMed ID: 12637342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Safety and economic efficiency of platelet IIb/IIIa receptor blockers in acute coronary syndromes without ST-segment elevation].
    Latour-Pérez J
    Rev Esp Cardiol; 2000 Aug; 53(8):1148-50. PubMed ID: 11032540
    [No Abstract]   [Full Text] [Related]  

  • 26. Glycoprotein IIb-IIIa inhibitors in unstable coronary syndromes and percutaneous interventions--a conservative approach.
    De Caterina R; Di Gioacchino L
    Rev Port Cardiol; 2003; 22(7-8):995-1002. PubMed ID: 14587167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
    Chiang TM; Zhu J
    Thromb Res; 2005; 115(6):503-8. PubMed ID: 15792682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basic and clinical aspects of platelet integrin alphaIIbbeta3 receptor antagonists in acute coronary syndromes.
    Goudevenos JA; Tselepis AD
    Curr Opin Investig Drugs; 2001 Feb; 2(2):244-9. PubMed ID: 11816838
    [No Abstract]   [Full Text] [Related]  

  • 29. Tirofiban and emergency coronary surgery.
    Shanmugam G
    Eur J Cardiothorac Surg; 2005 Oct; 28(4):546-50. PubMed ID: 16126403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
    J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit.
    Schneider DJ; Aggarwal A
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):903-13. PubMed ID: 15500435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
    Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
    Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet activation and progression to complications.
    Kereiakes DJ; Michelson AD
    Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition.
    Chew DP; Moliterno DJ
    J Am Coll Cardiol; 2000 Dec; 36(7):2028-35. PubMed ID: 11127436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cell adhesion molecule].
    Ikeda H
    Nihon Rinsho; 1998 Oct; 56(10):2493-9. PubMed ID: 9796308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of platelets and platelet glycoprotein IIb/IIIa receptor inhibition in acute coronary syndromes: an educational supplement. Introduction.
    Joseph A
    J Emerg Med; 1999; 17(3):565. PubMed ID: 10338257
    [No Abstract]   [Full Text] [Related]  

  • 39. Intravenous glycoprotein IIb/IIIa antagonists: their benefits, problems and future developments.
    Curtin R
    Curr Pharm Des; 2004; 10(14):1577-85. PubMed ID: 15134556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A perspective on the toxicological mechanisms possibly contributing to the failure of oral glycoprotein IIb/IIIa antagonists in the clinic.
    Sy SK; Levenstadt AL
    Am J Cardiovasc Drugs; 2004; 4(1):1-10. PubMed ID: 14967061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.